- Agreement to encompass co-development and optimization of protocols for intensified and continuous viral vector production for cell and gene therapies and vaccine applications
- NevoLine™ Upstream platform and scale-X™ bioreactors featured at GMP facility in Guangzhou, China to be used to accelerate scale-up from pilot to clinical to commercial scales
Belgium and Guangzhou, China – Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral vector production, has formed a worldwide strategic partnership with VectorBuilder, a global leader in vector design, optimization and manufacturing. Univercells Technologies will work with VectorBuilder’s manufacturing center in Guangzhou, China to develop and optimize platform processes using best-in-class technologies for the production of custom viral vectors for cell and gene therapies as well as vaccine applications.
With rapid advances in cell and gene therapy in recent years as well as intensified interests in recombinant viral vaccines brought on by COVID19, the demand for custom viral vectors, especially GMP-grade vectors, has significantly increased. Yet traditional manufacturing technologies lack the cost-effectiveness and scalability to accommodate this growing demand. With this partnership, both companies aim at combining capabilities, services, and existing technologies to develop a portfolio of optimized viral vector manufacturing protocols maximizing customers’ performance and commercialization success.
“We are extremely pleased to partner with Univercells Technologies to co-develop optimized, scalable and customizable solutions for fast and affordable production of viral vectors. This partnership is an important step in VectorBuilder’s ambition to become a global leader in high performance commercial-scale biomanufacturing”, says Dr. Jason Ye, Vice President of Biomanufacturing of VectorBuilder.
“We are very excited to partner with VectorBuilder, a global pioneer in custom viral vector manufacturing,” stated Mathias Garny, CEO of Univercells Technologies. “With the complementarity of both companies’ expertise and know-how, we can maximize the benefits of our manufacturing technologies and offer an unparalleled solution for integrated continuous manufacture for VectorBuilder’s customers.”
Both the scale-X bioreactors portfolio and the NevoLine Upstream platform offer high-performing production capacities while drastically reducing footprint and costs. The scale-X hydro (2.4 m2) and carbo (10 and 30 m2) bioreactors are a great asset for accelerating process development and supporting clinical validation. Complemented by the NevoLine™ Upstream platform with integrated scale-X nitro (200 and 600 m2) bioreactor the comprehensive technology range offered by Univercells Technologies enables a seamless transition to commercial manufacture.
The scale-X hydro and carbo systems and the NevoLine Upstream platform are employed for process optimization in VectorBuilder’s state-of-the-art GMP Process Development facility in Guangzhou, China for intensified and continuous vector manufacturing at commercial scale.
Special thanks to the General Consulate of Belgium in Guangzhou, China and AWEX for supporting us in organizing the signing ceremony.
About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.
Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.
LinkedIn: Univercells Technologies
VectorBuilder is a rapidly growing biotechnology company specializing in advanced genetic engineering solutions for research and medicine. In particular, VectorBuilder has established itself as the global leader in a range of products and services related to gene delivery, including vector design and optimization, vector cloning, virus packaging, library construction and screening, stable cell line generation, and GMP manufacturing of clinical-grade plasmids, mRNAs, proteins and viruses.
One highlight of VectorBuilder’s innovative solutions is its revolutionary online platform for designing and ordering custom vectors. This award-winning platform has become highly popular with researchers around the world and has grown into an industry standard for its rich functionalities, extensive experimental validations, and easy-to-use graphical interface. By leveraging the popularity of this platform, VectorBuilder has built a comprehensive portfolio of offerings covering virtually all gene delivery needs from bench to bedside.